Celera completes its corporate transformation

Celera has ended its run as a biotech drug developer, completing its switch to molecular diagnostic testing company and moving its HQ from Rockville, MD to Alameda California. The Baltimore Business Journal tracked the arc of the company from high-flying genomics player to drug developer to molecular diagnostic testing company as it officially splits from Applera. Once counting a staff of 550, the Rockville operations have declined steadily over the years and have now reportedly been reduced to about 25. Acquisitions and expansions in California, meanwhile, swelled that staff to 550.

"It's a new day for Celera as we emerge as an independent healthcare company focused on personalizing disease management," said CEO Kathy Ordonez. "Our employees and our newly formed board of directors are energized about working together to build a successful future for our growing business, with its promising pipeline of new products and strong balance sheet."

- check out Celera's release
- read the report from the Baltimore Business Journal

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.